Brief: Helix Biopharma presents topline l-dos47 results
06/12/2016 13:31
Dec 6 (Reuters) - Helix Biopharma Corp HBP.TO -
* Helix Biopharma Corp presents topline l-dos47 results at
the 17th iasclc world conference on lung cancer
* Forty-Four , or 80% of patients in safety population had
at least one treatment emergent adverse events
Source text for Eikon: ID:nCCN4YNysV
Further company coverage: HBP.TO
((bangalore.newsroom@thomsonreuters.com))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020